miRNA‑148a regulates the expression of the estrogen receptor through DNMT1‑mediated DNA methylation in breast cancer cells

Xu,Yurui; Chao,Lin; Wang,Jianyu; Sun,Yonghong

doi:10.3892/ol.2017.6803

miRNA‑148a regulates the expression of the estrogen receptor through DNMT1‑mediated DNA methylation in breast cancer cells

Authors:
- Yurui Xu
- Lin Chao
- Jianyu Wang
- Yonghong Sun
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Wuxi No. 2 People's Hospital, Wuxi, Jiangsu 214000, P.R. China
Published online on: August 23, 2017 https://doi.org/10.3892/ol.2017.6803
Pages: 4736-4740
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer remains the most prevalent cancer among women worldwide. The expression of estrogen receptor‑α (ER‑α) is an important marker for prognosis. ER‑α status may be positive or negative in breast cancer cells, although the cause of negative or positive status is not yet fully characterized. In the present study, the expression of ER‑α and miRNA‑148a was assessed in two breast cancer cell lines, HCC1937 and MCF7. An association between ER‑α and miRNA‑148a expression was identified. It was then demonstrated that DNA methyltransferase 1 (DNMT1) is a target of miRNA‑148a, which may suppress the expression of ER‑α via DNA methylation. Finally, an miRNA‑148a mimic or inhibitor was transfected into MCF7 cells; the miRNA‑148a mimic increased ER‑α expression whereas the miRNA‑148a inhibitor decreased ER‑α expression. In conclusion, it was identified that miRNA‑148a regulates ER‑α expression through DNMT1‑mediated DNA methylation in breast cancer cells. This may represent a potential miRNA‑based strategy to modulate the expression of ER‑α and provide a novel perspective for investigating the role of miRNAs in treating breast cancer.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Giacinti L, Claudio PP, Lopez M and Giordano A: Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist. 11:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
3	Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M and Forbes JF: ATAC/LATTE investigators: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the atac trial. Lancet Oncol. 11:1135–1141. 2010. View Article : Google Scholar : PubMed/NCBI
4	Martínez-Galán J, Torres-Torres B, Núñez MI, López-Peñalver J, Del Moral R, De Almodóvar Ruiz JM, Menjón S, Concha A, Chamorro C, Ríos S and Delgado JR: Esr1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer. 14:592014. View Article : Google Scholar : PubMed/NCBI
5	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
6	Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
7	Yahya SM and Elsayed GH: A summary for molecular regulations of miRNAs in breast cancer. Clin Biochem. 48:388–396. 2015. View Article : Google Scholar : PubMed/NCBI
8	Yan L, Nass SJ, Smith D, Nelson WG, Herman JG and Davidson NE: Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther. 2:552–556. 2003. View Article : Google Scholar : PubMed/NCBI
9	Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, Qi YT, Li W, Lu B, Peiper SS, et al: A regulatory circuit of mir-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13. 2013. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Huang B, Warner M and Gustafsson JÅ: Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol 418 Pt. 3:240–244. 2015. View Article : Google Scholar
12	Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR and Sloane JP: Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol. 155:1811–1815. 1999. View Article : Google Scholar : PubMed/NCBI
13	Liu Y, Liu R, Fu P, Du F, Hong Y, Yao M, Zhang X and Zheng S: N1-guanyl-1,7-diaminoheptane sensitizes estrogen receptor negative breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation. Cell Physiol Biochem. 36:2494–2503. 2015. View Article : Google Scholar : PubMed/NCBI
14	de Souza Rocha, Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, et al: Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 70:9175–9184. 2010. View Article : Google Scholar : PubMed/NCBI
15	Wang YS, Chou WW, Chen KC, Cheng HY, Lin RT and Juo SH: MicroRNA-152 mediates DNMT1-regulated DNA methylation in the estrogen receptor α gene. PLoS One. 7:e306352012. View Article : Google Scholar : PubMed/NCBI
16	Chen Y, Song YX and Wang ZN: The microRNA-148/152 family: Multi-faceted players. Mol Cancer. 12:432013. View Article : Google Scholar : PubMed/NCBI
17	Razin A and Szyf M: DNA methylation patterns. Formation and function. Biochim Biophys Acta. 782:331–342. 1984. View Article : Google Scholar : PubMed/NCBI
18	Szyf M: DNA methylation signatures for breast cancer classification and prognosis. Genome Med. 4:262012. View Article : Google Scholar : PubMed/NCBI
19	Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW and Huang TH: CpG island arrays: An application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res. 6:1432–1438. 2000.PubMed/NCBI
20	Li E, Bestor TH and Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 69:915–926. 1992. View Article : Google Scholar : PubMed/NCBI
21	Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, Dai CY and Juo SH: OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: A novel mechanism for cardiovascular diseases. FASEB J. 25:1718–1728. 2011. View Article : Google Scholar : PubMed/NCBI
22	Huang J, Wang Y, Guo Y and Sun S: Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 52:60–70. 2010. View Article : Google Scholar : PubMed/NCBI
23	Braconi C, Huang N and Patel T: MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 51:881–890. 2010.PubMed/NCBI
24	Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
25	Anders CK and Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 9 Suppl 2:S73–S81. 2009. View Article : Google Scholar : PubMed/NCBI
26	Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L and Tomao S: Triple-negative breast cancer: New perspectives for targeted therapies. Onco Targets Ther. 8:177–193. 2015. View Article : Google Scholar : PubMed/NCBI
27	Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI